4:50 PM
 | 
Aug 08, 2017
 |  BC Extra  |  Politics & Policy

FDA to hold workshop on structured benefit-risk assessment

FDA will hold a public workshop on Sept. 18 to discuss the structured assessment of benefit and risk for drug and biologic candidates under review. The workshop will discuss regulatory and industry experiences with structured benefit-risk assessments and...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >